GSK’s Arexvy receives expanded approval in Canada
GSK’s (LSE: GSK) Arexvy (RSV vaccine) has received an expanded approval in Canada to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 50-59 who are at increased risk.
This approval broadens its prior authorization for adults aged 60 and above, and follows similar regulatory approvals in the USA and the EU. GSK has also filed regulatory submissions for Japan and other geographies, with decisions anticipated soon.
The expansion highlights the risks faced by adults with chronic conditions such as chronic obstructive pulmonary disease, asthma, diabetes, and heart failure. In Canada, 98% of adults hospitalized with RSV are found to have at least one preexisting condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze